Edesa Historical Balance Sheet

EDSA Stock

USD 1.78 0.12 6.32%

Trend analysis of Edesa Biotech balance sheet accounts such as Total Current Liabilities of 1.3 M or Total Stockholder Equity of 6.4 M provides information on Edesa Biotech's total assets, liabilities, and equity, which is the actual value of Edesa Biotech to its prevalent stockholders. By breaking down trends over time using Edesa Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Edesa Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edesa Biotech is a good buy for the upcoming year.

Edesa Biotech Inventory

(1.07 Million)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

About Edesa Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Edesa Biotech at a specified time, usually calculated after every quarter, six months, or one year. Edesa Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Edesa Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Edesa currently owns. An asset can also be divided into two categories, current and non-current.

Edesa Biotech Balance Sheet Chart

At present, Edesa Biotech's Other Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3 M, whereas Total Assets are forecasted to decline to about 8.7 M.

Total Assets Total Current Liabilities Non Current Assets Total Cash And Short Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of Edesa Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Edesa Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Edesa Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Edesa Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Edesa Biotech balance sheet. This account contains Edesa Biotech investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Edesa Biotech fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from Edesa Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Other Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3 M, whereas Total Assets are forecasted to decline to about 8.7 M.

	2021	2022	2023	2024 (projected)
Non Current Assets Total	2.5M	2.5M	2.8M	3.0M
Cash	7.1M	5.4M	6.2M	5.6M

Non Current Assets Total Cash

Edesa Biotech balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant And Equipment Net	Net Receivables	Property Plant And Equipment Gross	Current Deferred Revenue	Non Current Liabilities Total	Intangible Assets	Common Stock Total Equity	Inventory	Common Stock	Short Term Investments	Other Assets
Total Assets		0.23	0.35	0.75	-0.8	-0.59	0.81	0.41	-0.02	0.89	0.23	0.51	0.1	0.26	0.97	0.21	0.32	0.24	-0.38	0.19	0.73	0.44	-0.14	0.6	0.45	0.14
Other Current Liab	0.23		0.8	-0.29	-0.29	-0.27	0.31	0.0	0.08	0.28	0.12	-0.13	0.46	0.73	0.27	-0.1	0.05	-0.1	0.57	0.59	-0.23	-0.09	-0.02	0.02	-0.18	-0.28
Total Current Liabilities	0.35	0.8		-0.21	-0.4	-0.24	0.43	0.25	0.2	0.27	0.26	0.06	0.52	0.79	0.31	-0.33	0.13	-0.32	0.26	0.6	-0.09	-0.3	-0.21	-0.02	0.09	-0.11
Total Stockholder Equity	0.75	-0.29	-0.21		-0.34	-0.57	0.36	0.44	0.07	0.58	0.28	0.59	-0.05	-0.44	0.69	0.32	0.39	0.35	-0.56	-0.48	0.86	0.56	-0.24	0.75	0.66	0.19
Net Debt	-0.8	-0.29	-0.4	-0.34		0.28	-0.99	-0.14	0.09	-0.82	-0.04	-0.31	-0.07	-0.59	-0.83	0.0	-0.14	0.0	0.21	-0.59	-0.45	-0.17	-0.02	-0.19	-0.04	-0.16
Retained Earnings	-0.59	-0.27	-0.24	-0.57	0.28		-0.32	-0.49	-0.47	-0.53	-0.47	-0.01	-0.45	0.02	-0.53	-0.36	-0.02	-0.41	0.11	0.17	-0.54	-0.57	0.32	-0.93	-0.38	0.49
Cash	0.81	0.31	0.43	0.36	-0.99	-0.32		0.21	-0.01	0.81	0.13	0.32	0.14	0.59	0.83	-0.04	0.15	-0.04	-0.17	0.57	0.47	0.15	-0.04	0.23	0.08	0.15
Non Current Assets Total	0.41	0.0	0.25	0.44	-0.14	-0.49	0.21		0.62	0.05	0.89	0.55	0.58	-0.09	0.21	-0.36	0.47	-0.33	-0.19	-0.27	0.39	-0.15	-0.81	0.45	0.64	0.17
Non Currrent Assets Other	-0.02	0.08	0.2	0.07	0.09	-0.47	-0.01	0.62		-0.19	0.88	0.04	0.78	-0.13	-0.14	-0.51	0.12	-0.48	0.15	-0.31	0.14	-0.3	-0.76	0.35	0.41	-0.26
Cash And Short Term Investments	0.89	0.28	0.27	0.58	-0.82	-0.53	0.81	0.05	-0.19		-0.07	0.14	-0.06	0.37	0.96	0.45	-0.05	0.45	-0.24	0.36	0.62	0.64	0.25	0.51	0.16	-0.05
Common Stock Shares Outstanding	0.23	0.12	0.26	0.28	-0.04	-0.47	0.13	0.89	0.88	-0.07		0.4	0.75	-0.1	0.06	-0.54	0.4	-0.5	0.06	-0.3	0.29	-0.31	-0.89	0.39	0.6	0.04
Other Current Assets	0.51	-0.13	0.06	0.59	-0.31	-0.01	0.32	0.55	0.04	0.14	0.4		0.05	-0.17	0.39	-0.34	0.84	-0.32	-0.5	-0.25	0.43	-0.21	-0.58	0.1	0.59	0.69
Other Stockholder Equity	0.1	0.46	0.52	-0.05	-0.07	-0.45	0.14	0.58	0.78	-0.06	0.75	0.05		0.21	0.0	-0.47	0.16	-0.44	0.42	0.0	-0.11	-0.34	-0.63	0.25	0.14	-0.39
Total Liab	0.26	0.73	0.79	-0.44	-0.59	0.02	0.59	-0.09	-0.13	0.37	-0.1	-0.17	0.21		0.31	-0.18	-0.13	-0.19	0.31	0.96	-0.27	-0.21	0.17	-0.28	-0.35	-0.08
Total Current Assets	0.97	0.27	0.31	0.69	-0.83	-0.53	0.83	0.21	-0.14	0.96	0.06	0.39	0.0	0.31		0.31	0.22	0.33	-0.33	0.27	0.67	0.53	0.05	0.53	0.31	0.09
Property Plant And Equipment Net	0.21	-0.1	-0.33	0.32	0.0	-0.36	-0.04	-0.36	-0.51	0.45	-0.54	-0.34	-0.47	-0.18	0.31		-0.42	1.0	-0.25	-0.07	0.24	0.91	0.61	0.46	-0.13	-0.33
Net Receivables	0.32	0.05	0.13	0.39	-0.14	-0.02	0.15	0.47	0.12	-0.05	0.4	0.84	0.16	-0.13	0.22	-0.42		-0.4	-0.23	-0.22	0.13	-0.32	-0.66	0.09	0.36	0.42
Property Plant And Equipment Gross	0.24	-0.1	-0.32	0.35	0.0	-0.41	-0.04	-0.33	-0.48	0.45	-0.5	-0.32	-0.44	-0.19	0.33	1.0	-0.4		-0.26	-0.09	0.26	0.92	0.58	0.5	-0.11	-0.34
Current Deferred Revenue	-0.38	0.57	0.26	-0.56	0.21	0.11	-0.17	-0.19	0.15	-0.24	0.06	-0.5	0.42	0.31	-0.33	-0.25	-0.23	-0.26		0.27	-0.52	-0.27	0.14	-0.21	-0.47	-0.46
Non Current Liabilities Total	0.19	0.59	0.6	-0.48	-0.59	0.17	0.57	-0.27	-0.31	0.36	-0.3	-0.25	0.0	0.96	0.27	-0.07	-0.22	-0.09	0.27		-0.32	-0.15	0.35	-0.37	-0.5	-0.04
Intangible Assets	0.73	-0.23	-0.09	0.86	-0.45	-0.54	0.47	0.39	0.14	0.62	0.29	0.43	-0.11	-0.27	0.67	0.24	0.13	0.26	-0.52	-0.32		0.49	-0.15	0.66	0.71	0.29
Common Stock Total Equity	0.44	-0.09	-0.3	0.56	-0.17	-0.57	0.15	-0.15	-0.3	0.64	-0.31	-0.21	-0.34	-0.21	0.53	0.91	-0.32	0.92	-0.27	-0.15	0.49		0.46	0.67	0.02	-0.35
Inventory	-0.14	-0.02	-0.21	-0.24	-0.02	0.32	-0.04	-0.81	-0.76	0.25	-0.89	-0.58	-0.63	0.17	0.05	0.61	-0.66	0.58	0.14	0.35	-0.15	0.46		-0.25	-0.55	-0.17
Common Stock	0.6	0.02	-0.02	0.75	-0.19	-0.93	0.23	0.45	0.35	0.51	0.39	0.1	0.25	-0.28	0.53	0.46	0.09	0.5	-0.21	-0.37	0.66	0.67	-0.25		0.46	-0.4
Short Term Investments	0.45	-0.18	0.09	0.66	-0.04	-0.38	0.08	0.64	0.41	0.16	0.6	0.59	0.14	-0.35	0.31	-0.13	0.36	-0.11	-0.47	-0.5	0.71	0.02	-0.55	0.46		0.42
Other Assets	0.14	-0.28	-0.11	0.19	-0.16	0.49	0.15	0.17	-0.26	-0.05	0.04	0.69	-0.39	-0.08	0.09	-0.33	0.42	-0.34	-0.46	-0.04	0.29	-0.35	-0.17	-0.4	0.42

Click cells to compare fundamentals

Edesa Biotech Account Relationship Matchups

Edesa Biotech balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Liab	(69.7K)	1.4M	(19.0K)	1.7M	1.6M	1.7M
Total Current Liabilities	1.5M	1.5M	2.1M	1.8M	2.1M	1.3M
Total Stockholder Equity	6.6M	13.1M	9.4M	7.0M	8.1M	6.4M
Net Debt	(7.0M)	(7.7M)	(7.1M)	(5.3M)	(4.7M)	(5.0M)
Retained Earnings	(13.1M)	(26.5M)	(44.0M)	(52.4M)	(47.2M)	(44.8M)
Cash	7.2M	7.8M	7.1M	5.4M	6.2M	5.6M
Non Current Assets Total	2.7M	2.5M	2.5M	2.5M	2.8M	3.0M
Cash And Short Term Investments	7.2M	7.8M	7.1M	5.4M	6.2M	6.8M
Common Stock Shares Outstanding	1.2M	1.7M	2.1M	2.9M	3.3M	3.5M
Liabilities And Stockholders Equity	10.8M	14.6M	11.6M	8.9M	10.2M	8.7M
Other Current Assets	802.9K	1.9M	745.5K	448.9K	516.2K	402.8K
Other Stockholder Equity	1.6M	4.9M	11.2M	13.0M	15.0M	15.7M
Total Liab	4.1M	1.5M	2.2M	1.8M	2.1M	2.3M
Total Current Assets	8.1M	12.1M	9.1M	6.4M	7.4M	7.6M
Property Plant And Equipment Net	174.8K	111.6K	31.2K	100.1K	90.1K	85.6K
Net Receivables	87.4K	3.3M	1.3M	626.5K	720.5K	521.2K
Property Plant And Equipment Gross	174.8K	145.4K	70.7K	143.9K	129.5K	123.1K
Accumulated Other Comprehensive Income	(287.2K)	(205.3K)	(213.6K)	(214.6K)	(246.8K)	(234.5K)
Non Current Liabilities Total	2.6M	67.7K	43.7K	19.8K	17.8K	16.9K
Inventory	224.3K	(217.1K)	(87.4K)	(1.3M)	(1.1M)	(1.1M)
Common Stock	18.5M	34.9M	42.5M	46.6M	53.6M	39.4M
Property Plant Equipment	73.1K	174.8K	111.6K	31.2K	28.0K	26.6K
Accounts Payable	1.5M	1.4M	2.1M	1.7M	2.0M	1.2M
Net Tangible Assets	5.3M	4.1M	10.7M	7.1M	8.2M	4.3M
Net Invested Capital	6.6M	13.1M	9.4M	7.0M	8.1M	9.4M
Net Working Capital	6.6M	10.6M	7.0M	4.6M	4.2M	5.8M
Capital Stock	18.5M	34.9M	42.5M	46.6M	53.6M	38.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:

How To Invest In Edesa

Details

Is Edesa Stock a good investment?

Details

What is Edesa Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(19.78)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.72)

Return On Equity

(1.29)

The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edesa Historical Balance Sheet

Edesa Biotech Inventory

(1.07 Million)

About Edesa Balance Sheet Analysis

Edesa Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Non Current Assets Total

Cash And Short Term Investments

Edesa Biotech balance sheet Correlations

Edesa Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Edesa Biotech balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.97	Total Assets
Total Current Assets	+ 0.96	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.96	Total Liab
Common Stock Total Equity	+ 0.92	Property Plant And Equipment Gross
Common Stock Total Equity	+ 0.91	Property Plant And Equipment Net

Cash	- 0.99	Net Debt
Common Stock	- 0.93	Retained Earnings
Inventory	- 0.89	Common Stock Shares Outstanding
Total Current Assets	- 0.83	Net Debt
Cash And Short Term Investments	- 0.82	Net Debt
Inventory	- 0.81	Non Current Assets Total